Inhibikase Therapeutics, Inc. (IKT)

Market Cap	16.87M
Revenue (ttm)	61,818
Net Income (ttm)	-18.82M
Shares Out	28.03M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,813
Open	0.602
Previous Close	0.600
Day's Range	0.602 - 0.644
52-Week Range	0.440 - 1.520
Beta	0.97
Analysts	Sell
Price Target	6.12 (+916.61%)
Earnings Date	Mar 30, 2023

About IKT

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 23, 2020
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: IKT

Financial Performance

In 2021, IKT's revenue was $3.10 million, an increase of 343.92% compared to the previous year's $698,468. Losses were -$14.79 million, 419.2% more than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for IKT stock is "Sell." The 12-month stock price forecast is $6.12, which is an increase of 916.61% from the latest price.

Price Target

$6.12

(916.61% upside)

Analyst Consensus: Sell